Target ranges of oxygen saturation in extremely preterm infants
- PMID: 20472937
- PMCID: PMC2891970
- DOI: 10.1056/NEJMoa0911781
Target ranges of oxygen saturation in extremely preterm infants
Abstract
Background: Previous studies have suggested that the incidence of retinopathy is lower in preterm infants with exposure to reduced levels of oxygenation than in those exposed to higher levels of oxygenation. However, it is unclear what range of oxygen saturation is appropriate to minimize retinopathy without increasing adverse outcomes.
Methods: We performed a randomized trial with a 2-by-2 factorial design to compare target ranges of oxygen saturation of 85 to 89% or 91 to 95% among 1316 infants who were born between 24 weeks 0 days and 27 weeks 6 days of gestation. The primary outcome was a composite of severe retinopathy of prematurity (defined as the presence of threshold retinopathy, the need for surgical ophthalmologic intervention, or the use of bevacizumab), death before discharge from the hospital, or both. All infants were also randomly assigned to continuous positive airway pressure or intubation and surfactant.
Results: The rates of severe retinopathy or death did not differ significantly between the lower-oxygen-saturation group and the higher-oxygen-saturation group (28.3% and 32.1%, respectively; relative risk with lower oxygen saturation, 0.90; 95% confidence interval [CI], 0.76 to 1.06; P=0.21). Death before discharge occurred more frequently in the lower-oxygen-saturation group (in 19.9% of infants vs. 16.2%; relative risk, 1.27; 95% CI, 1.01 to 1.60; P=0.04), whereas severe retinopathy among survivors occurred less often in this group (8.6% vs. 17.9%; relative risk, 0.52; 95% CI, 0.37 to 0.73; P<0.001). There were no significant differences in the rates of other adverse events.
Conclusions: A lower target range of oxygenation (85 to 89%), as compared with a higher range (91 to 95%), did not significantly decrease the composite outcome of severe retinopathy or death, but it resulted in an increase in mortality and a substantial decrease in severe retinopathy among survivors. The increase in mortality is a major concern, since a lower target range of oxygen saturation is increasingly being advocated to prevent retinopathy of prematurity. (ClinicalTrials.gov number, NCT00233324.)
2010 Massachusetts Medical Society
Figures
Comment in
-
CPAP and low oxygen saturation for very preterm babies?N Engl J Med. 2010 May 27;362(21):2024-6. doi: 10.1056/NEJMe1004342. Epub 2010 May 16. N Engl J Med. 2010. PMID: 20472938 No abstract available.
-
Target ranges of oxygen saturation in extremely preterm infants.N Engl J Med. 2010 Sep 23;363(13):1285; author reply 1285-6. doi: 10.1056/NEJMc1007912. N Engl J Med. 2010. PMID: 20860514 No abstract available.
-
Oxygen-saturation targets in preterm infants.N Engl J Med. 2013 May 30;368(22):2141-2. doi: 10.1056/NEJMe1305534. Epub 2013 May 5. N Engl J Med. 2013. PMID: 23642082 No abstract available.
-
Re: Time to Change NRP.Pediatrics. 2017 May;139(5):e20170452A. doi: 10.1542/peds.2017-0452A. Pediatrics. 2017. PMID: 28557766 No abstract available.
-
Authors' Response.Pediatrics. 2017 May;139(5):e20170452B. doi: 10.1542/peds.2017-0452B. Pediatrics. 2017. PMID: 28557768 No abstract available.
References
-
- Duc G, Sinclair JC. Oxygen administration. In: Sinclair JC, Bracken MB, editors. Effective care of the newborn infant. Oxford University Press; New York: 1992. pp. 178–94.
-
- Bolton DP, Cross KW. Further observations on cost of preventing retrolental fibroplasia. Lancet. 1974;303:445–8. - PubMed
-
- Chow LC, Wright KW, Sola A. Can changes in clinical practice decrease the incidence of severe retinopathy of prematurity in very low birth weight infants? Pediatrics. 2003;111:339–45. - PubMed
-
- Anderson CG, Benitz WE, Madan A. Retinopathy of prematurity and pulse oximetry: a national survey of recent practices. J Perinatol. 2004;24:164–8. - PubMed
Publication types
MeSH terms
Substances
Associated data
Grants and funding
- U10 HD27851/HD/NICHD NIH HHS/United States
- U10 HD40521/HD/NICHD NIH HHS/United States
- M01 RR000030/RR/NCRR NIH HHS/United States
- UL1 RR025744/RR/NCRR NIH HHS/United States
- UG1 HD040492/HD/NICHD NIH HHS/United States
- U10 HD21397/HD/NICHD NIH HHS/United States
- U10 HD21385/HD/NICHD NIH HHS/United States
- U10 HD027856/HD/NICHD NIH HHS/United States
- U10 HD40689/HD/NICHD NIH HHS/United States
- U10 HD021373/HD/NICHD NIH HHS/United States
- K23 HD041423/HD/NICHD NIH HHS/United States
- UL1 RR024139/RR/NCRR NIH HHS/United States
- U10 HD021385/HD/NICHD NIH HHS/United States
- M01 RR44/RR/NCRR NIH HHS/United States
- U10 HD40492/HD/NICHD NIH HHS/United States
- U10 HD53119/HD/NICHD NIH HHS/United States
- M01 RR59/RR/NCRR NIH HHS/United States
- U10 HD053124/HD/NICHD NIH HHS/United States
- UL1 RR25008/RR/NCRR NIH HHS/United States
- U10 HD053119/HD/NICHD NIH HHS/United States
- M01 RR6022/RR/NCRR NIH HHS/United States
- U10 HD53124/HD/NICHD NIH HHS/United States
- U10 HD21364/HD/NICHD NIH HHS/United States
- U10 HD34216/HD/NICHD NIH HHS/United States
- UL1 RR25744/RR/NCRR NIH HHS/United States
- U10 HD021364/HD/NICHD NIH HHS/United States
- U10 HD027880/HD/NICHD NIH HHS/United States
- M01 RR70/RR/NCRR NIH HHS/United States
- U10 HD36790/HD/NICHD NIH HHS/United States
- U10 HD040521/HD/NICHD NIH HHS/United States
- U10 HD053109/HD/NICHD NIH HHS/United States
- U10 HD27880/HD/NICHD NIH HHS/United States
- M01 RR008084/RR/NCRR NIH HHS/United States
- UG1 HD053089/HD/NICHD NIH HHS/United States
- U10 HD27904/HD/NICHD NIH HHS/United States
- M01 RR125/RR/NCRR NIH HHS/United States
- UL1 TR001449/TR/NCATS NIH HHS/United States
- M01 RR633/RR/NCRR NIH HHS/United States
- U10 HD53109/HD/NICHD NIH HHS/United States
- U10 HD040461/HD/NICHD NIH HHS/United States
- U10 HD40498/HD/NICHD NIH HHS/United States
- M01 RR016587/RR/NCRR NIH HHS/United States
- U10 HD53089/HD/NICHD NIH HHS/United States
- U10 HD27871/HD/NICHD NIH HHS/United States
- M01 RR7122/RR/NCRR NIH HHS/United States
- U10 HD040689/HD/NICHD NIH HHS/United States
- U10 HD040492/HD/NICHD NIH HHS/United States
- M01 RR64/RR/NCRR NIH HHS/United States
- U10 HD027853/HD/NICHD NIH HHS/United States
- U10 HD027904/HD/NICHD NIH HHS/United States
- UL1 RR24979/RR/NCRR NIH HHS/United States
- U10 HD021397/HD/NICHD NIH HHS/United States
- U10 HD27856/HD/NICHD NIH HHS/United States
- U10 HD27853/HD/NICHD NIH HHS/United States
- M01 RR39/RR/NCRR NIH HHS/United States
- M01 RR30/RR/NCRR NIH HHS/United States
- U10 HD40461/HD/NICHD NIH HHS/United States
- UG1 HD034216/HD/NICHD NIH HHS/United States
- UL1 TR000454/TR/NCATS NIH HHS/United States
- U10 HD027871/HD/NICHD NIH HHS/United States
- UL1 TR000041/TR/NCATS NIH HHS/United States
- M01 RR007122/RR/NCRR NIH HHS/United States
- U10 HD027851/HD/NICHD NIH HHS/United States
- UG1 HD027880/HD/NICHD NIH HHS/United States
- M01 RR80/RR/NCRR NIH HHS/United States
- M01 RR16587/RR/NCRR NIH HHS/United States
- M01 RR8084/RR/NCRR NIH HHS/United States
- M01 RR54/RR/NCRR NIH HHS/United States
- M01 RR997/RR/NCRR NIH HHS/United States
- U10 HD21373/HD/NICHD NIH HHS/United States
- UG1 HD053109/HD/NICHD NIH HHS/United States
- M01 RR750/RR/NCRR NIH HHS/United States
- UG1 HD027851/HD/NICHD NIH HHS/United States
- UL1 RR025008/RR/NCRR NIH HHS/United States
- M01 RR32/RR/NCRR NIH HHS/United States
- U10 HD034216/HD/NICHD NIH HHS/United States
- U10 HD036790/HD/NICHD NIH HHS/United States
- UL1 RR24139/RR/NCRR NIH HHS/United States
- U10 HD040498/HD/NICHD NIH HHS/United States
- M01 RR006022/RR/NCRR NIH HHS/United States
- U10 HD053089/HD/NICHD NIH HHS/United States
- UL1 RR024979/RR/NCRR NIH HHS/United States
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Molecular Biology Databases